Ascentage Pharma Group International (AAPG)

Market Cap	1.64B -59.3%
Revenue (ttm)	82.08M -41.5%
Net Income	-177.68M
EPS	-0.50
Shares Out	370.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,876
Open	17.92
Previous Close	18.20
Day's Range	17.40 - 18.20
52-Week Range	16.36 - 48.45
Beta	0.67
Analysts	Strong Buy
Price Target	47.56 (+161.33%)
Earnings Date	Aug 19, 2026

About AAPG

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 24, 2025
• Employees: 767
• Stock Exchange: NASDAQ
• Ticker Symbol: AAPG
• Website: https://www.ascentage.cn

Financial Performance

In 2025, AAPG's revenue was 574.12 million, a decrease of -41.46% compared to the previous year's 980.65 million. Losses were -1.24 billion, 206.5% more than in 2024.

Financial numbers in CNY

Analyst Summary

According to 9 analysts, the average rating for AAPG stock is "Strong Buy." The 12-month stock price target is $47.56, which is an increase of 161.33% from the latest price.

Price Target

$47.56

(161.33% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 19, 2026

Data Sources Report a data error